Difference between revisions of "Human Longevity, Inc."

From H+Pedia
Jump to navigation Jump to search
m (consolidated citations for same reference)
m (fix citation)
 
Line 1: Line 1:
'''Human Longevity, Inc.''' (also simply known as the acronym '''HLI''') is a [[Wikipedia:Genome|genomic]] [[Life extension|life-extension]] company based in California.<ref name="wired">Rundle, Michael. (24 April 2015). [https://www.wired.co.uk/article/brad-perkins-human-longevity-wired-health-2015 "'Supercharged' genomics: 100 years of breakthroughs possible in 10 years"]. ''Wired UK''. "Based in San Diego, Human Longevity is fixed on using genome data and analytics to develop new ways to fight age-related diseases."</ref><ref name="economist" />https://www.economist.com/news/briefing/21704788-fight-cheat-death-hotting-up-adding-ages</ref> It was co-founded by [[J. Craig Venter]], who led one of the first teams to sequence the human genome.<ref name="cnbc">Ferris, Robert. (19 July 2016). [https://www.cnbc.com/2016/07/19/this-biotech-wants-to-radically-extend-human-lifespan.html "This biotech wants to radically extend human lifespan"]. ''CNBC''. "'It is the most comprehensive physical you can get,' said company co-founder J. Craig Venter, on 'Squawk Box.' [...] Venter led one of the two teams of scientists who first sequenced the human genome."</ref><ref>https://www.humanlongevity.com/about/overview/</ref><ref>https://www.humanlongevity.com/our-science/</ref> Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging.<ref name="wired" /> The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016.<ref>http://www.humanlongevity.com/human-longevity-inc-completes-220-million-series-b-financing/</ref> It has made deals with companies Celgene and AstraZeneca to collaborate in its research.
+
'''Human Longevity, Inc.''' (also simply known as the acronym '''HLI''') is a [[Wikipedia:Genome|genomic]] [[Life extension|life-extension]] company based in California.<ref name="wired">Rundle, Michael. (24 April 2015). [https://www.wired.co.uk/article/brad-perkins-human-longevity-wired-health-2015 "'Supercharged' genomics: 100 years of breakthroughs possible in 10 years"]. ''Wired UK''. "Based in San Diego, Human Longevity is fixed on using genome data and analytics to develop new ways to fight age-related diseases."</ref><ref name="economist">https://www.economist.com/news/briefing/21704788-fight-cheat-death-hotting-up-adding-ages</ref> It was co-founded by [[J. Craig Venter]], who led one of the first teams to sequence the human genome.<ref name="cnbc">Ferris, Robert. (19 July 2016). [https://www.cnbc.com/2016/07/19/this-biotech-wants-to-radically-extend-human-lifespan.html "This biotech wants to radically extend human lifespan"]. ''CNBC''. "'It is the most comprehensive physical you can get,' said company co-founder J. Craig Venter, on 'Squawk Box.' [...] Venter led one of the two teams of scientists who first sequenced the human genome."</ref><ref>https://www.humanlongevity.com/about/overview/</ref><ref>https://www.humanlongevity.com/our-science/</ref> Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging.<ref name="wired" /> The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016.<ref>http://www.humanlongevity.com/human-longevity-inc-completes-220-million-series-b-financing/</ref> It has made deals with companies Celgene and AstraZeneca to collaborate in its research.
  
 
While it is conducting research, the company is offering a wellness service known as "Health Nucleus", which offers customers a range of medical tests such as a full genome sequencing and tests for early indications of cancers, Alzheimer's and heart disease.<ref name="economist" /> This testing is meant to help people catch diseases earlier than otherwise possible and to identify risk factors for diseases later in life.<ref name="cnbc" />
 
While it is conducting research, the company is offering a wellness service known as "Health Nucleus", which offers customers a range of medical tests such as a full genome sequencing and tests for early indications of cancers, Alzheimer's and heart disease.<ref name="economist" /> This testing is meant to help people catch diseases earlier than otherwise possible and to identify risk factors for diseases later in life.<ref name="cnbc" />

Latest revision as of 14:32, 21 April 2019

Human Longevity, Inc. (also simply known as the acronym HLI) is a genomic life-extension company based in California.[1][2] It was co-founded by J. Craig Venter, who led one of the first teams to sequence the human genome.[3][4][5] Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging.[1] The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016.[6] It has made deals with companies Celgene and AstraZeneca to collaborate in its research.

While it is conducting research, the company is offering a wellness service known as "Health Nucleus", which offers customers a range of medical tests such as a full genome sequencing and tests for early indications of cancers, Alzheimer's and heart disease.[2] This testing is meant to help people catch diseases earlier than otherwise possible and to identify risk factors for diseases later in life.[3]

At the start of 2017 the company hired Cynthia Collins from GE Healthcare, and Venter became Executive Chair. The company's chief operating office, Mark Winham, left the company in mid-2017, and Collins and the company's chief medical officer, Brad Perkins, left in December of that year in 2017. Venter stepped back into the CEO role, but announced in May 2018 that he was leaving the company to return to the J. Craig Venter Institute.[7] Venter was sued for allegedly 'stealing trade secrets' at Human Longevity.[8] The case has been dismissed.[9]

Further reading

External links

References